Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121)

Brandon M. Brown, Heesung Shim, Miao Zhang, Vladimir Yarov-Yarovoy and Heike Wulff
Molecular Pharmacology July 31, 2017, mol.117.109421; DOI: https://doi.org/10.1124/mol.117.109421
Brandon M. Brown
1 Univesity of California, Davis;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heesung Shim
2 University of Calfornia, Davis;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miao Zhang
3 Chapman University School of Pharmacy, Irvine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Yarov-Yarovoy
4 University of California, Davis;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heike Wulff
5 Unviersity of California, Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Small-conductance (KCa2) and intermediate-conductance (KCa3.1) calcium-activated K+ channels are voltage-independent and share a common calcium/calmodulin mediated gating mechanism. Most existing positive gating modulators like EBIO, NS309 or SKA-31 activate both channels with similar potencies. We previously performed a structure activity relationship study with the aim of optimizing the benzothiazole pharmacophore of SKA-31 towards KCa3.1 selectivity and identified SKA-121 (5-methylnaphtho[2,1-d]oxazol-2-amine), which displays 40-fold selectivity for KCa3.1 over KCa2.3. In order to understand why introduction of a single CH3 group in 5-position of the benzothiazole/oxazol system could achieve such a gain in selectivity for KCa3.1 over KCa2.3 we first localized the binding site of the benzothiazoles/oxazoles to the calmodulin binding domain (CaM-BD)/CaM interface and then used the RosettaLigand computational modeling software to generate models of the KCa3.1 and KCa2.3 CaM-BD/CaM complexes with SKA-121. Based on a combination of mutagenesis and structural modeling we suggest that all benzothiazoles/oxazoles-type KCa activators bind relatively "deep" in the CaM-BD/CaM interface and hydrogen-bond with E54 on CaM. In KCa3.1 SKA-121 forms an additional hydrogen-bond network with R362. NS309 in contrast sits more "forward" and directly hydrogen-bonds with R362 in KCa3.1. Mutating R362 to serine, the corresponding residue in KCa2.3 significantly reduces the potency of SKA-121 suggesting that R362 is responsible for the generally greater potency of KCa activators on KCa3.1. The increase in SKA-121's KCa3.1 selectivity compared with its parent SKA-31 seems to be due to better overall shape complementarity and hydrophobic interactions with S372, M368 on KCa3.1 and M72 on CaM at the KCa3.1-CaM-BD/CaM interface.

  • Func. analysis receptor/ion channel mutants
  • Homology modeling
  • Structure-activity relationships and modeling
  • Potassium channels
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 103 (4)
Molecular Pharmacology
Vol. 103, Issue 4
1 Apr 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121)
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121)

Brandon M. Brown, Heesung Shim, Miao Zhang, Vladimir Yarov-Yarovoy and Heike Wulff
Molecular Pharmacology July 31, 2017, mol.117.109421; DOI: https://doi.org/10.1124/mol.117.109421

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121)

Brandon M. Brown, Heesung Shim, Miao Zhang, Vladimir Yarov-Yarovoy and Heike Wulff
Molecular Pharmacology July 31, 2017, mol.117.109421; DOI: https://doi.org/10.1124/mol.117.109421
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Pharmacological characterization of the human α6β4 nAChR
  • Mechanism of the selective action of paraherquamide A
  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics